Synthesis and Characterization of Related Substances of Torasemide

Jiong Chen; Wei Ming; De-Hua Fan; Shuang-Xi Gu

doi:10.1055/s-0042-1749327

Pharmaceutical Fronts, Inhaltsverzeichnis

CC BY 4.0 · Pharmaceutical Fronts 2022; 04(03): e157-e161
DOI: 10.1055/s-0042-1749327

Original Article

Synthesis and Characterization of Related Substances of Torasemide

Autor*innen

Jiong Chen

¹Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, People's Republic of China
Wei Ming

¹Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, People's Republic of China
De-Hua Fan

²Wuhan Jianuokang Pharmaceutical Technology Co., Ltd., Wuhan, People's Republic of China
Shuang-Xi Gu

¹Key Laboratory for Green Chemical Process of Ministry of Education, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan, People's Republic of China

³Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, Wuhan Institute of Technology, Wuhan, People's Republic of China

Abstract

Torasemide, a pyridine-3-sulfonylurea derivative, is a high-efficiency loop diuretic. During the process development of torasemide, five process-related substances, which have been specified in the pharmacopeia, would be produced. In this study, all these related substances, including compounds A–E, were synthesized via simple procedures and subsequently characterized by ¹H nuclear magnetic resonance (NMR), ¹³C NMR, and mass spectrometry. Particularly, a simple synthetic method for compound A has not been found in previous literature. It is worth noting that other related substances could be prepared from compound B in one or two steps. The availability of these related substances could allow for quality control in the process of torasemide.

Keywords

torasemide - loop diuretic - related substances - synthesis - process development

Volltext

Referenzen

References
1 Szekely G, Amores de Sousa MC, Gil M, Castelo Ferreira F, Heggie W. Genotoxic impurities in pharmaceutical manufacturing: sources, regulations, and mitigation. Chem Rev 2015; 115 (16) 8182-8229
2 Tang P, Nie B, Huang JZ, Zhang YJ, Zhang J, Chen FE. Recent advances of pharmaceutical process chemistry and its innovation in China: part 1. Pharm Fronts 2020; 2 (01) e28-e54
3 Yue Y, Luo XF, Zhong WY, Hou W. Advances in researches on impurities in chemical drugs. Prog Pharm Sci 2015; 39 (07) 533-539
4 Kang JL. Discussion on impurity profile analysis of synthetic drug substances. Carol J Pharm 2016; 47 (08) 1093-1096
5 Dongbang S, Confair DN, Ellman JA. Rhodium-catalyzed C-H alkenylation/electrocyclization cascade provides dihydropyridines that serve as versatile intermediates to diverse nitrogen heterocycles. Acc Chem Res 2021; 54 (07) 1766-1778
6 Kaldas SJ, O'Keefe KTV, Mendoza-Sanchez R, Yudin AK. Amphoteric borylketenimines: versatile intermediates in the synthesis of borylated heterocycles. Chem Eur J 2017; 23 (41) 9711-9715
7 Liu XY, Shen JF. Progress in clinical research on a new diuretic torasemide. Shanghai Med Pharm J 2007; 28 (05) 219-221
8 Hua L, Li YS, Song Z. Torasemide, a new loop diuretics. Chin J New Drug 2003; 12 (11) 888-892
9 Stirling A, Fisher M. Torasemide. Pract Diabetes 2018; 35 (03) 106-107
10 Manolis A, Kallistratos M, Doumas M. Torasemide in hypertension and heart failure: re-inventing loop diuretic therapy?. Curr Pharm Des 2021; 27 (23) 2714-2721
11 Arie G, Marina E, Dmitry G. et al. Process for the preparation of highly pure torsemide. WO Patent 2003097603A1. November, 2003
12 Che DQ, Guntoori BR, Duncan SC. Process for the preparation of torsemide and related intermediates. U.S. Patent 7378527B2. September, 2005
13 Wei WY, Huo LR, Yang XB. et al. Method for preparing torasemide and its derivatives. CN Patent 104744355A. July, 2015
14 Xiong ZH, Fei XN. Synthesis of a new, curative and effective medicine for hypertension and diuretic torasemide. Chinese J Med Chem 2002; 12 (04) 219-221
15 Zhang LW, Shu Q, Yin L. et al. A process for preparing torasemide and its crystal forms. CN Patent 102702089A. October, 2012
16 Zhao SM, Shang JP, Li Q, Luo ZF. Study on synthesis of torasemid. Fine Chem Intermed 2009; 39 (06) 29-30
17 Masereel B, Renard P, Schynts M, Pirotte B, de Tullio P, Delarge J. Synthesis and pharmacology of pyrid-3-yl sulfonylureas and thioureas as astrocytic Na⁺ 2C1⁻ K⁺ cotransporter inhibitors. Eur J Med Chem 1994; 29 (07) 527-535
18 Bozdag M, Alafeefy AM, Altamimi AM, Vullo D, Carta F, Supuran CT. Coumarins and other fused bicyclic heterocycles with selective tumor-associated carbonic anhydrase isoforms inhibitory activity. Bioorg Med Chem 2017; 25 (02) 677-683
19 Ismail MA, Abou El Ella DA, Abouzid KA, Mahmoud AH. Integrated structure-based activity prediction model of benzothiadiazines on various genotypes of HCV NS5b polymerase (1a, 1b and 4) and its application in the discovery of new derivatives. Bioorg Med Chem 2012; 20 (07) 2455-2478
20 Venkatesh Y, Nandi S, Shee M, Saha B. Bis-acetyl carbazole: a photoremovable protecting group for sequential release of two different functional groups and its application in therapeutic release. Eur J Org Chem 2017; (41) 6121-6130

Zusatzmaterial

Supplementary Material (PDF) (opens in new window)